Drug Candidate Marketplace

Drug Candidate Marketplace lists the information of drug candidates, therapeutic targets and drug discovery technologies. Visitors can use search functions based on the interests and needs. If you have a drug candidates, therapeutic targets and drug discovery technologies that you are interested in and would like to gain more information, please contact us by clicking the inquiry button. After consenting to the terms of condition and use of our services, the requested information will be provided to you.

Date Candidate Mechanism of action Indication Route Development stage Note
08/31/18 GEM040 Topical anti-inflammatory Joint pain, Muscle pain, Gout, Local inflammatory pain see Note Preclinical Topical formulations of Ibuprofen, Naproxen, Diclofenac to use in the treatment of inflamatory pain and related conditions
Formulation shows 5 to 10X increase human skin permeation coupled
Potential for OTC or RX introduction: minimal development timeline

08/31/18 GEM039 Antifungal Onychomy- cosis see Note Preclinical Novel and unique topical formulation of Terbenafine with exceptional permeation (40 fold) across the human nail.
Potential for OTC or RX introduction: minimal development timeline

08/31/18 GEM038 Locally acting anti-inflammatory- Trigeminal neuro-inflammation Migraine Phase 2a Clinical POC in acute migraine therapy in Phase 2a
Efficacy comparable to Triptans but with no systemic side effects or restrictions
Shortened development timelines (NDA:2021)
Product opportunity for use in Temporomandibular Joint Disease and trigeminal neuralgias
08/31/18 GEM037 Allosteric modulator of the CCR3 receptor Asthma, rhinitis Oral Phase 2a In phase 2a:
Highly significant effects on the methacholine provocative response
Showed trends to improvement in EAR (Early Phase Allergic Response)
Reduced induced sputum eosinophil percentage and increased percent blood eosinophil
08/27/18 GEM036 Hematopoietic stem cell fucosylation Prevention of infection & GvHD from hematopoietic stem cell transplantation see Note Phase 3 ready with FDA SPA In Phase II study:
Statistically significant acceleration of immune system reconstitution
(neutrophil/platelet recovery)
Significantly reduced infection and GvHD
Improved survival
Positioned to be best-in-classNo
reports of adverse event specifically attributable to fucosylation

08/07/18 GEM035 An anti-ENO1 antibody Immune diseases, various cancers SC Preclinical (close to IND) Showed efficacy in animal models of multiple sclerosis, RA, pancreatic cancer and liver cancer.
Also applicable to IBD and COPD etc.
Completed pre-clinical studies including monkey toxicity studies, GMP production.
08/07/18 GEM034 Derivative of neuroprotective protein Stroke, Huntington chorea, Schizophrenia and PTSD IV Preclinical A cell-permeable recombinant peptide.
Can cross the blood-brain barrier, is resistant to degradation, and can bind constitutively to its substrates.
Significantly reduces brain damage in rodent stroke model.
Expected to be treated after stroke without diagnosis of stroke type before dosing.
08/07/18 GEM033 Inhibitors of bacterial resistance mechanisms Gram-negative MDR bacterial infections, lung infections in cystic fibrosis (CF) patients see Note Preclinical Restore effectiveness of shelved antibiotics.
Lower the effective dose of antibiotics.
Mitigate antibiotic resistance.
Disrupt biofilm-based infections.
Over 1,000 compounds with lead compounds for each indication identified.

Route : Intravenous, Aerosol, Topical
07/26/18 GEM032 Calcium release-activated calcium channel inhibitor Respiratory & immuno-inflammatory diseases Oral Phase 1 - Preclinical study demonstrated the therapeutic potential in respiratory diseases causally associated with allergic inflamation.
- Phase 1 SAD/MAD study were completed.
07/26/18 GEM031 Calcium release-activated calcium channel inhibitor Lymphomas & Solid cancer Oral Phase 1 - Demonstrated preclinical activity in a broad range of cancers.
- Phase 1 dose-escalation study in patients with relapsed or refractory lymphomas is ongoing.